We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

159 hedge funds and large institutions have $1.24B invested in Portola Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 64 increasing their positions, 46 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more call options, than puts

Call options by funds: $4.22M | Put options by funds: $1.78M

39% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 46

15% more capital invested

Capital invested by funds: $1.08B → $1.24B (+$158M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

5% less funds holding

Funds holding: 167159 (-8)

21% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 28

Holders
159
Holders Change
-8
Holders Change %
-4.79%
% of All Funds
4.24%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
22
Increased
64
Reduced
46
Closed
28
Calls
$4.22M
Puts
$1.78M
Net Calls
+$2.45M
Net Calls Change
-$21.9M
Name Holding Trade Value Shares
Change
Change in
Stake
CAM
26
Cormorant Asset Management
Massachusetts
$9.35M -$7.51M -304,000 -43%
Norges Bank
27
Norges Bank
Norway
$9.3M
Morgan Stanley
28
Morgan Stanley
New York
$9.17M +$2.38M +96,505 +33%
Balyasny Asset Management
29
Balyasny Asset Management
Illinois
$9.16M +$3M +121,539 +46%
O
30
OrbiMed
New York
$8.75M -$11.5M -467,200 -56%
Renaissance Technologies
31
Renaissance Technologies
New York
$8.25M -$3.1M -125,400 -26%
AllianceBernstein
32
AllianceBernstein
Tennessee
$8.08M
UBS AM
33
UBS AM
Illinois
$7.5M -$285K -11,542 -4%
Lazard Asset Management
34
Lazard Asset Management
New York
$6.88M +$3.85M +155,863 +115%
Bank of New York Mellon
35
Bank of New York Mellon
New York
$5.99M +$91.2K +3,692 +1%
TCIM
36
TIAA CREF Investment Management
New York
$5.51M +$406K +16,445 +8%
FIM
37
Fernwood Investment Management
Massachusetts
$5.5M +$941K +38,100 +20%
Prudential Financial
38
Prudential Financial
New Jersey
$5.43M +$2.33M +94,521 +70%
RSCM
39
Rail-Splitter Capital Management
Illinois
$5.22M +$5.47M +221,414 New
NI
40
Numeric Investors
Massachusetts
$4.94M -$9.29M -376,256 -64%
HCM
41
Harvey Capital Management
Florida
$4.87M +$1.35M +54,850 +36%
OAM
42
Oxford Asset Management
United Kingdom
$4.65M +$4.87M +197,199 New
Charles Schwab
43
Charles Schwab
California
$4.46M +$88.1K +3,570 +2%
BIM
44
BlackRock Investment Management
Delaware
$4.37M +$304K +12,293 +7%
PI
45
Putnam Investments
Massachusetts
$4.33M -$2.05K -83 -0%
RSCM
46
Rock Springs Capital Management
Maryland
$4.13M
Bank of America
47
Bank of America
North Carolina
$3.63M -$67.9K -2,750 -2%
Invesco
48
Invesco
Georgia
$3.48M +$1.13M +45,771 +45%
Jacobs Levy Equity Management
49
Jacobs Levy Equity Management
New Jersey
$3.25M +$374K +15,150 +12%
SIM
50
Spark Investment Management
New York
$3.14M -$205K -8,300 -6%

PTLA Hedge Fund Activity: Q2 2016 in Review

159 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q2 2016, worth a combined $1.24B — up 15% from $1.08B a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of PTLA and 22 opened new positions — a net loss of 6 holders — while 46 trimmed existing stakes and 64 added.

The largest buyer was Pictet Asset Management (UK), adding an estimated $15M. The largest seller was Franklin Resources, cutting an estimated $18.3M.

  • 159 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q2 2016, down from 167 in Q1 2016.
  • Funds reported $1.24B of Portola Pharmaceuticals, Inc. stock for Q2 2016, up 15% quarter-over-quarter.
  • 22 funds opened new Portola Pharmaceuticals, Inc. positions in Q2 2016 and 28 closed out, a net change of -6 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q2 2016 was Pictet Asset Management (UK), an estimated $15M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q2 2016 was Franklin Resources, an estimated $18.3M sold.

Based on aggregated 13F filings for Q2 2016.